Correction to: Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy

John W. Day (), Jerry R. Mendell, Eugenio Mercuri, Richard S. Finkel, Kevin A. Strauss, Aaron Kleyn, Sitra Tauscher-Wisniewski, Francis Fonyuy Tukov, Sandra P. Reyna and Deepa H. Chand
Additional contact information
John W. Day: Stanford University Medical Center
Jerry R. Mendell: Nationwide Children’s Hospital
Eugenio Mercuri: Catholic University
Richard S. Finkel: Nemours Children’s Hospital
Kevin A. Strauss: Clinic for Special Children
Aaron Kleyn: Novartis Gene Therapies, Inc.
Sitra Tauscher-Wisniewski: Novartis Gene Therapies, Inc.
Francis Fonyuy Tukov: Novartis Gene Therapies, Inc.
Sandra P. Reyna: Novartis Gene Therapies, Inc.
Deepa H. Chand: Novartis Gene Therapies, Inc.

Drug Safety, 2022, vol. 45, issue 2, No 9, 192 pages

Date: 2022
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-021-01130-7 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:45:y:2022:i:2:d:10.1007_s40264-021-01130-7

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-021-01130-7

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().